Bottom line
Is MSVEX a good fund? The bottom line
MSVEX is the Class A share class of Vitality Portfolio, a managed other mutual fund from Morgan Stanley.
It charges 1.3% — about $130 a year on every $10,000 invested, more expensive than 92% of other funds we track.
It returned +8.7% over one year (as of Dec 31, 2025, per its prospectus).
This share class carries a front-end sales charge of up to 5.25%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.3%)
- Front-end sales load up to 5.25%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What MSVEX invests in
The Vitality Portfolio (the Fund) seeks long-term capital appreciation.
Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in securities of companies located in the United States that are principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare. These companies include, but are not limited to, biotechnology, pharmaceuticals, medical equipment and supplies, healthcare technology, healthcare providers and services, and life sciences tools and services. The Fund may also allocate to industries related to the healthcare industry, but are not primarily engaged in the scientific advancement of healthcare. The allocation among these areas will vary depending on the relative potential the Adviser sees within each area and the outlook for the overall healthcare sector. ? The Adviser emphasizes a bottom-up stock selection…
From the fund's prospectus (filed Apr 30, 2026).
MSVEX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MSVEX | +8.7% | — | — |
| Other median | +9.2% | +4.9% | +5.3% |
Source: Fund prospectus, as of Dec 31, 2025
What MSVEX costs
On a $10,000 investment, MSVEX's 1.3% expense ratio costs about $130 a year. The prospectus estimates $10,017 in total costs over 10 years (assuming 5% annual returns). The median other fund charges 0.95%.